Phase 2 Retatrutide Trial Summary: Triple-Agonist Weight Loss

Design

Randomized, double-blind, placebo-controlled, dose-ranging phase 2 trial enrolling 338 adults with BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity) without diabetes. Participants were randomized to one of six retatrutide dose groups (1 mg, 4 mg with two escalation schedules, 8 mg, and 12 mg with two escalation schedules) or placebo, administered by once-weekly subcutaneous injection. Retatrutide is a single-molecule triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors — the first compound of this class to enter clinical development. The treatment duration was 48 weeks, with slower escalation schedules designed to improve gastrointestinal tolerability.

Primary result

Weight loss was dose-dependent and substantial across all retatrutide groups. Mean body weight change at 48 weeks was -8.7% (1 mg), -17.1% (4 mg), -22.8% (8 mg), and -24.2% (12 mg), compared with -2.1% for placebo. At the 12 mg dose, the mean weight loss of 24.2% exceeded the results achieved by any previously reported anti-obesity pharmacotherapy, including semaglutide 2.4 mg (approximately 15% in STEP-1) and tirzepatide 15 mg (approximately 21% in SURMOUNT-1). Among participants receiving the 12 mg dose, 100% lost at least 5% of body weight, 93% lost at least 10%, 83% lost at least 15%, and 63% lost at least 20%.

Secondary outcomes

Retatrutide produced dose-dependent improvements in cardiometabolic markers including waist circumference, systolic blood pressure, triglycerides, and HbA1c. At the highest doses, waist circumference reductions exceeded 18 cm. Hepatic fat fraction, measured by MRI-based proton density fat fraction in a subset of participants, decreased by more than 80% from baseline in the 8 mg and 12 mg groups — a particularly notable finding given the growing recognition of metabolic dysfunction-associated steatotic liver disease as a major comorbidity of obesity. The weight loss trajectory at 48 weeks had not yet plateaued in the higher-dose groups, suggesting that longer treatment could yield even greater reductions.

Adverse events

Gastrointestinal adverse events were the most frequent: nausea (varying from 16% at 1 mg to 43% at 12 mg), diarrhea (14-34%), vomiting (7-23%), and constipation (6-19%). GI events were most common during dose escalation and generally diminished over time. The slower escalation schedule for the 4 mg and 12 mg doses reduced the incidence and severity of GI events compared with the faster escalation schedules. Discontinuation due to adverse events ranged from 0% at 1 mg to 16% at 12 mg. No pancreatitis cases were reported. Heart rate increased by 2-4 beats per minute in the higher-dose groups, consistent with the class effect of incretin-based therapies. No concerning safety signals emerged in liver enzymes, lipase, or amylase.

Interpretation

This phase 2 trial established retatrutide as the most potent anti-obesity pharmacotherapy reported to date. The addition of glucagon receptor agonism to the dual GIP/GLP-1 mechanism appears to drive weight loss beyond what dual agonism alone achieves, likely through glucagon's effects on energy expenditure, hepatic lipid metabolism, and appetite regulation. The magnitude of weight loss at the 12 mg dose — approaching bariatric surgery outcomes — represents a potential step-change in pharmacologic obesity treatment. However, this was a phase 2 trial with relatively small per-group numbers (approximately 40-50 per arm), and the safety and efficacy of retatrutide requires confirmation in larger, longer phase 3 trials. The dramatic reduction in hepatic fat is particularly noteworthy and positions retatrutide as a potential treatment for MASLD. Phase 3 trials (the TRIUMPH program) are underway.